Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamsulosin for benign prostatic hyperplasia.

T J Wilt1, R Mac Donald, I Rutks

  • 1General Internal Medicine (111-0), Minneapolis VA/VISN 23 Center for Chronic Disease Outcomes Research, One Veterans Drive, Minneapolis, Minnesota 55417, USA. Tim.Wilt@med.va.gov

The Cochrane Database of Systematic Reviews
|January 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply by Authors.

The Journal of urology·2020
Same author

Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

Prostate cancer and prostatic diseases·2011
Same author

Clinical Evidence: Non-metastatic prostate cancer.

The Western journal of medicine·2008
Same author

Five-alpha-reductase Inhibitors for prostate cancer prevention.

The Cochrane database of systematic reviews·2008
Same author

Microwave thermotherapy for benign prostatic hyperplasia.

The Cochrane database of systematic reviews·2007
Same author

Intermittent versus continuous androgen suppression for prostatic cancer.

The Cochrane database of systematic reviews·2007

Tamsulosin offers moderate symptom relief for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Higher doses increase adverse effects, with effectiveness plateauing.

Area of Science:

  • Urology
  • Pharmacology
  • Evidence-based Medicine

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS) in men.
  • Effective management of BPH aims to alleviate these bothersome symptoms.

Purpose of the Study:

  • To systematically review the efficacy and safety of tamsulosin for treating LUTS associated with BPH.
  • To compare tamsulosin with placebo, other medications, and surgical interventions.

Main Methods:

  • Systematic review of randomized controlled trials.
  • Inclusion criteria: men with BPH, tamsulosin vs. placebo/other treatments, clinical outcomes, duration ≥30 days.
  • Data extraction and analysis focused on symptom scores, flow rates, and adverse events.

Related Experiment Videos

Main Results:

  • 14 studies (4,122 subjects) analyzed; tamsulosin improved symptoms and peak urine flow compared to placebo.
  • Effectiveness was similar to other alpha-antagonists; higher doses showed minimal additional benefit.
  • Adverse events, including dizziness and abnormal ejaculation, increased significantly with higher tamsulosin doses (0.8 mg).

Conclusions:

  • Tamsulosin provides moderate improvement in urinary symptoms and flow for BPH patients.
  • Effectiveness is comparable to other alpha-antagonists, with limited gains from higher doses.
  • Increased adverse effects and withdrawal rates observed with higher tamsulosin doses; long-term data and BPH progression impact are undetermined.